RE:RE:RE:RE:RE:RE:RE:BioCloud salesPaul has given me impression that he is all about building value with a long term perspective in mind and ownership is important. I trust that consistent with this view, if dilution is needed, he would be looking at best value and if this BioCloud journey is just beginning, I cannot see that uplisting would trump issuing shares at a higher share price just to get uplisted. It is not like shares cannot appreciate considerably on the CSE. There are companies that will always do better on the CSE, and it is all about the share price at the end of the day. For a buyout, fundamentals will be what the acquirers will be valuing.